GlassScriptPhysician profile
Jaimita V Patel
NPI 1851442677
$10,525.97
in general payments reported to CMS, 2019-2025
60 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $1,538 · 2021: $1,567 · 2022: $1,644 · 2023: $1,388 · 2024: $1,496 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,782.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $984.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $908.04 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $852.62 | 2019-2025 | |
| Amgen INC. | $820.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $608.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $582.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $362.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $319.29 | 2019-2023 | Spravato |
| Abbott Laboratories | $296.03 | 2019-2025 | Proclaim, Freestyle Libre 3, Lamitrode |
| Amarin Pharma, INC. | $231.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $202.41 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $188.12 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $182.94 | 2019-2022 | |
| Astellas Pharma US INC | $133.56 | 2023-2025 | Veozah, Myrbetriq |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaimita Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.